Today, we signed a supply agreement with Dutch Company Cell4Pharma to access their industry-validated conditionally immortalized Renal Proximal Tubule
CN Bio FDA collaboration expanded
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to
NAFLD vs MASLD: could a name change impact the progression of liver disease research?
Liver disease is a serious worldwide problem linked to approximately two million deaths per year and in many cases is entirely preventable (Sumeet et
Introducing the PhysioMimix® OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ
Flowing to the beat of your heart
How mimicking blood flow makes Organ-on-a-chip technology even more life-like With every beat of your heart, blood rushes through your body. Some
How a novel in vitro Liver-on-a-chip model of fatty liver disease is being used to help prevent a global healthcare crisis.
Obesity is a global epidemic. Up to a third of the USA’s adult population is now obese and worldwide, the prevalence of obesity has almost tripled
CN Bio’s PhysioMimix® technology receives FDA recognition
FDA publication demonstrates advantages of PhysioMimix® in drug safety and metabolism applications, over standard techniques Represents the first
Life in the fastlane
How a partnership between the FDA and Organ-on-a-chip developers has the potential to fast-track drug development From a small discovery in a research